Treace Medical Concepts

General Information

We are a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions). We have pioneered our proprietary Lapiplasty 3D Bunion Correction System – a combination of novel instruments, implants and surgical methods designed to improve the inconsistent clinical outcomes of traditional approaches to bunion surgery. Although bunions are deformities typically caused by an unstable joint in the middle of the foot that leads to a three-dimensional (3D) misalignment in the foot’s anatomical structure, the majority of traditional surgical approaches focus on correcting the deformity from a two-dimensional (2D) perspective and therefore fail to address the root cause of the disorder. To effectively restore the normal anatomy of bunion patients and improve clinical outcomes, we believe addressing the root cause of the bunion is critical and have developed the Lapiplasty System to correct the deformity across all three anatomic dimensions. Our mission is to be the leader in the surgical treatment of bunions by establishing the Lapiplasty System as the standard of care.

A bunion is a painful, disfiguring deformity characterized by a deviated position of the great toe, and easily identified visually by the “bump” at its base. Bunions affect approximately 65 million Americans, and generally increase in prevalence and severity over time. Nearly 25% of adults between the ages of 18 and 65, and over 35% of people over the age of 65, have bunions. Approximately 4.4 million patients in the United States seek medical attention for bunions annually; of these patients, an estimated 1.1 million are deemed surgical candidates, which represents a total annual addressable market opportunity of more than $5 billion. 

Employees: 133
Founded: 2014
Contact Information
Address 203 Fort Wade Rd., Suite 150 Ponte Vedra, Florida 32081
Phone Number (904) 373-5940
Web Address
View Prospectus: Treace Medical Concepts
Financial Information
Market Cap $807.36mil
Revenues $57.37 mil (last 12 months)
Net Income $-4.31 mil (last 12 months)
IPO Profile
Symbol TMCI
Exchange NASDAQ
Shares (millions): 11.3
Price range $17.00 - $17.00
Est. $ Volume $191.3 mil
Manager / Joint Managers J.P. Morgan/ Morgan Stanley
CO-Managers SVB Leerink/ Stifel
Expected To Trade: 4/23/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change